Amgen
Pharma

NEJM retracts article on pivotal study for Amgen’s Tavneos

As Tavneos comes under intensifying pressure, Amgen faces a new hurdle with a leading medical journal’s retraction of the drug’s pivotal study data.
Eric Sagonowsky Jun 30, 2026 10:57am
FDA

Lilly, Regeneron among 7 chosen for FDA PreCheck Pilot Program

Jun 30, 2026 9:57am
Epkinly

AbbVie, Genmab's Epkinly redeems itself in DLBCL

Jun 30, 2026 9:50am
CMI Media Group bridges gaps in pharma marketing tech with newly launched Ad Astra platform

CMI's Ad Astra launch weaves together siloed pharma marketing tech

Jun 30, 2026 9:15am
red light stop light street traffic signal

Unicycive approval filing turned away by FDA again

Jun 30, 2026 9:03am
two arrows combining in merger

Klick bags Oxford PharmaGenesis in 3rd takeover in 18 months

Jun 30, 2026 6:00am
More News

BeOne’s Brukinsa hits goal in lymphoma confirmatory trial

Jun 30, 2026 6:00am

After trial fail, Teravance is bought out by Zymeworks for $929M

Jun 29, 2026 11:30am

FDA snubs Sobi’s gout drug over manufacturing issues

Jun 29, 2026 11:04am

Regulatory tracker: FDA starts review of Sandoz's generic GLP-1

Jun 29, 2026 10:30am